1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists

ChemMedChem

Volumn 1, Issue 2, 2006, Pages 245-255

  Heinrich, Timo ^a   Böttcher, Henning ^a   Prücher, Helmut ^a   Gottschlich, Rudolf ^a   Ackermann, Karl August ^a   Van Amsterdam, Christoph ^a  

^a MERCK KGAA   (Germany)

Author keywords

Insomnia; Medicinal chemistry; Neurotransmitters; Schizophrenia; Serotonin

Indexed keywords

PIPERIDINE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; ELECTROSPRAY MASS SPECTROMETRY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT;

ANIMALS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PIPERIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33646474851     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200500023     Document Type: Article

References (63)

1. a) W. Fischer, Pharm. Unserer Zeit 1991, 20, 21-31;
2. b) D. M. Barch, Psychopharmacology 2004, 174, 126-135;
3. c) D. C. Ohuoha, T. M. Hyde, J. F. Kleinman, Psychopharmacology 1993, 112 (1 Suppl.), 55-515;
4. d) J. E. Leysen, J. Physiol. 1981, 77 (2-3), 351-362.
5. D. Hoyer, G. R. Martin, Behav. Brain Res. 1996, 73, 263-268.
6. P. R. Hartig in Handbook of Experimental Pharmacology, Vol. 129 (Eds.; H. G. Baumgarten, M. Göthert), Springer, Berlin, 1997, Ch. 7, pp. 175-212.
7. a) G. K. Aghajanian, J. S. Sprouse, P. Sheldon, K. Rasmussen, Ann. N. Y. Acad. Sci. 1990, 600, 93-103;
8. b) D. Hoyer, D. E. Clarke, J. R. Fozard, P. R. Hartig, G. R. Martin, J. E. Mylecharane, P. R. Saxena, P. P. A. Humphry, Pharmacol. Rev. 1994, 46, 157-203;
9. c) T. Blank, R. Zwart, I. Nijholt, J. Spiess, J. Neurosci. Res. 1996, 45, 153-160;
10. d) J. E. Leysen, Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 11-26.
11. a) R. Glennon, M. Dukat, ID Res. Alert 1997, 2, 107-113;
12. b) G. A. Kennett, Curr. Res. Serotonin 1998, 3, 1-18.
13. a) G. Remington, S. Kapur, Psychopharmacology 2000, 148, 3-15;
14. b) W. Zhang, F. P. Bymaster, Psychopharmacology 1999, 141, 291-298.
15. a) D. J. Kennaway, R. W. Moyer, Brain Res. 1998, 806, 257-270;
16. b) G. Mayer, Pharmacopsychiatry 2003, 36, 150-155;
17. c) A. U. Viola, G. Brandenberger, M. Toussaint, P. Bouhours, J. P. Macher, R. Luthringer, Clin. Neurophysiol. 2002, 113, 429-434.
18. E. Holzinger, IDrugs 2005, 8, 410-415.
19. a) T. dePaulis, Curr. Opin. Invest. Drugs 2001, 2, 123-132;
20. b) L. A. Sorbera, J. Silvestre, J. Castaner, Drugs Future 1998, 23, 955-965;
21. c) J. H. Kehne, B. M. Baron, A. A. Carr, S. F. Chaney, J. Elands, D. J. Feldman, R. A. Frank, P. L. M. Van Giersbergen, T. C. McCloskey, M. P. Johnson, D. R. McCarthy, M. Poirot, Y. Senyah, B. W. Siegel, C. Widmaier, J. Pharmacol. Exp. Ther. 1996, 277, 968-981.
22. a) S. K. Hemrick-Luecke, D. C. Evans, Neuropharmacology 2002, 42, 162-169;
23. b) D. L. Willins, S. A. Berry, L. Alsayegh, J. R. Backstrom, E. Sanders-Bush, L. Friedman, B. L. Roth, Neuroscience 1999, 91, 599-606;
24. c) S. J. Offord, D. F. Wong, S. Nyberg, J. Clin. Pharmacol. 1999, Suppl 17S-24S;
25. d) C. J. Schmidt, G. M. Fadayel, C. K. Sullivan, V. L. Taylor, Eur. J. Pharmacol. 1992, 223, 65-74.
26. 2C 35).
27. E. H. Wong, A. Carlsson, L. Hansson, Proc. Natl. Acad. Sci. USA 1986, 83, 7104-7108.
28. P. Martin, N. Waters, A. Carlsson, M. L. Carlsson, J. Neural Transm. 1997, 104, 561-564.
29. S. J. Offord, CNP Congress, 1998, Glasgow, Scotland, abstract PT 10052.
30. Mean total scores for BPRS (brief psychiatric rating scale); mean scores for the negative and positive cluster of the BPRS; mean scores for SANS (scale for the assessment of negative symptoms); mean scores for Hamilton depression scale.
31. a) Scrip; July 1999, 2458, 21;
32. b) M. Rowley, L. J. Bristow, P. H. Hutson, J. Med. Chem. 2001, 44, 477-501.
33. M. Talvik-Lotfi, S. Nyberg, A. Nordstrom, H. Ito, C. Halldin, F. Brunner, L. Farde, Psychopharmacology 2000, 148, 400-403.
34. a) Aventis S.A. Company Presentation, February 5, 2004;
35. b) F. Polina, V. C. Sigrid, Am. J. Respirat. Crit. Care Med. 2003, 167, 563-569.
36. M. Rinaldi-Carmona, C. Congy, V. Santucci, J. Simiand, B. Gouret, G. Neliat, B. Labeeuw, G. Le Fur, P. Soubrie, J. C. Brelliere, J. Pharmacol. Exp. Ther. 1992, 262, 759-768.
37. Investigational Drugs Database Drug Report (413342), Ashley Publications, London, June 26, 2001.
38. J. P. Lindenmayer, A. Khan, Exp. Rev. Neurotherap. 2004, 4, 705-723.
39. C. A. Winstanley, D. E. H. Theobald, J. W. Dalley, J. C. Glennon, T. W. Robbins, Psychopharmacology 2004, 176, 376-385.
40. C. J. Schmidt, J. H. Kehne, A. A. Carr, CNS Drug Rev. 1997, 3, 49-67.
41. a) A. G. Bina, E. D. Daugs, J. C. Evans, H. Flemming, G. Guillamot, R. A. Hawthorne, T. H. E. Hilpert, J. E. Hitt, C. R. King, J. N. Koek, F. M. Laskovics, J. R. Lefler, A. L. Margolin, S. K. Minish, T. T. Ortyl, L. G. Rajewski, M. J. Sack, P. F. Skultety, S. K. Stolz-Dunn, A. L. Tigner, I. A. Tomlinson WO 9946245 A2 [Chem. Abstr. 1999, 131, 214195];
42. b) M. P. Johnson, B. W. Siegel, A. A. Carr, Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 354, 205-209.
43. D.-A. Kim, N. Lee, J. Y. Lee, D. H. Ryu, J.-S. Kim, S.-H. Lee, J.-Y. Choi, K. Chang, Y.-W. Kim, G.-J. Im, W.-S. Choi, T.-K. Kim, J.-H. Ryu, N.-H. Kim, K. Lee, Bioorg. Med. Chem. 2001, 9, 1609-1616.
44. R. C. Fuson, R. Gaertner, D. H. Chadwick, J. Org. Chem. 1948, 13, 489-495.
45. For example, see: J. T. Strupczewski, R. C. Allen, B. A. Gardner, B. L. Schmid, U. Stache, E. J. Glamkowski, M. C. Jones, D. B. Ellis, F. P. Huger, R. W. Dunn, J. Med. Chem. 1985, 28, 761-769.
46. M. Adachi, K. Sasakura, T. Sugasaw, Chem. Pharm. Bull. 1985, 33, 1826-1835.
47. The first hydrogenation yielded some of the corresponding pyridine alcohol. The latter could be hydrogenated to the desired product 15 in a second approach.
48. a) T. Heinrich, H. Böttcher, G. D. Bartoszyk, H. E. Greiner, C. A. Seyfried, C. van Amsterdam, J. Med. Chem. 2004, 47, 4677-4683;
49. b) T. Heinrich, H. Böttcher, R. Gericke, G. D. Bartoszyk, S. Anzali, C. A. Seyfried, H. E. Greiner, C. van Amsterdam, J. Med. Chem. 2004, 47, 4684-4692.
50. M. W. Dudley, N. L. Wiech, F. P. Miller, A. A. Carr, H. C. Cheng, L. E. Roebel, N. S. Doherty, H. I. Yamamura, R. C. Ursillo, M. G. Palfreyman, Drug Dev. Res. 1988, 13, 29-43.
51. C. J. Schmidt, J. M. Kehne, A. A. Carr, CNS Drug Rev. 1997, 3, 49-67.
52. T. Heinrich, H. Böttcher, G. D. Bartoszyk, H. Schwartz, S. Anzali, J. März, H. E. Greiner, C. A. Seyfried, Chimia 2004, 58, 143-147.
53. T. Heinrich, H. Böttcher, J. Leibrock, C. van Amsterdam, C. A. Seyfried, Drugs Future 2004, 29 (Suppl. A), 77.
54. a) G. D. Bartoszyk, C. van Amsterdam, H. Böttcher, C. A. Seyfried, Eur. J. Pharmacol. 2003, 473, 229-230;
55. b) D. Mamo, E. Sedman, J. Tillner, E. M. Sellers, M. K. Romach, S. Kapur, Psychopharmacology 2004, 175, 382-388.
56. For further information, see Supporting Information.
57. Nucleophilic substitution at the nitrogen atom of the building block used for X-ray crystallographic analysis with the 4-fluorophenethyl moiety gives (-)-53.
58. (R)-4-(2-chlorophenyl)-5,5-dimethyl-2-oxo-2λ*5*-[1,3, 2]dioxaphosphinan-2-ol.
59. a) D. O. Scott, T. G. Heath, J. Pharm. Biomed. Anal. 1998, 17, 17-25;
60. b) T. G. Heath, D. O. Scott, J. Am. Soc. Mass Spectrom. 1997, 8, 371-379.
61. M. Klockow, H. E. Greiner, A. Haase, C.-J. Schmitges, C. Seyfried, Drug Res. 1986, 36, 197-200.
62. A. Pazos, D. Hoyer, J. M. Palacios, Eur. J. Pharmacol. 1985, 106, 539-546.
63. D. W. Bonhaus, C. Bach, A. DeSouza, F. H. R. Salazar, B. D. Matsuoka, P. Zuppan, H. W. Chan, R. M. Eglen, Br. J. Pharmacol. 1995, 115, 622-628.